

TRADEMARK ASSIGNMENT

Electronic Version v1.1
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	SECURITY INTEREST

CONVEYING PARTY DATA

Name	Formerly	Execution Date	Entity Type
Altea Therapeutics Corporation		08/27/2009	CORPORATION: DELAWARE

RECEIVING PARTY DATA

Name:	GE Business Financial Services Inc.
Street Address:	2 Bethesda Metro Center
Internal Address:	Suite 600
City:	Bethesda
State/Country:	MARYLAND
Postal Code:	20814
Entity Type:	CORPORATION: MARYLAND

PROPERTY NUMBERS Total: 11

Property Type	Number	Word Mark
Registration Number:	3493784	ALTEA THERAPEUTICS
Registration Number:	3582860	ALTEA THERAPEUTICS
Registration Number:	3636717	MEDICINES MADE BETTER.
Registration Number:	3544534	PASSPORT
Serial Number:	77252691	MEDICINES MADE BETTER.
Serial Number:	78231096	PASSPORT
Serial Number:	78216875	MEDICINES MADE BETTER.
Serial Number:	78216870	SKIN-PORT
Serial Number:	78216864	SKINPORE
Serial Number:	76244463	MICROPOR
Serial Number:	78216796	SKINPORT

CORRESPONDENCE DATA

Fax Number: (202)408-3141

900144609

**TRADEMARK
 REEL: 004073 FRAME: 0501**

CH \$290.00 3493784

Correspondence will be sent via US Mail when the fax attempt is unsuccessful.

Phone: 800-927-9801 x2348
Email: jpaterso@cscinfo.com
Correspondent Name: Corporation Service Company
Address Line 1: 1090 Vermont Avenue NW, Suite 430
Address Line 2: Attn: Jean Paterson
Address Line 4: Washington, DISTRICT OF COLUMBIA 20005

ATTORNEY DOCKET NUMBER:	117306
NAME OF SUBMITTER:	Jean Paterson
Signature:	/jep/
Date:	10/05/2009

Total Attachments: 54

source=9-4-09 Altea-TM#page1.tif
source=9-4-09 Altea-TM#page2.tif
source=9-4-09 Altea-TM#page3.tif
source=9-4-09 Altea-TM#page4.tif
source=9-4-09 Altea-TM#page5.tif
source=9-4-09 Altea-TM#page6.tif
source=9-4-09 Altea-TM#page7.tif
source=9-4-09 Altea-TM#page8.tif
source=9-4-09 Altea-TM#page9.tif
source=9-4-09 Altea-TM#page10.tif
source=9-4-09 Altea-TM#page11.tif
source=9-4-09 Altea-TM#page12.tif
source=9-4-09 Altea-TM#page13.tif
source=9-4-09 Altea-TM#page14.tif
source=9-4-09 Altea-TM#page15.tif
source=9-4-09 Altea-TM#page16.tif
source=9-4-09 Altea-TM#page17.tif
source=9-4-09 Altea-TM#page18.tif
source=9-4-09 Altea-TM#page19.tif
source=9-4-09 Altea-TM#page20.tif
source=9-4-09 Altea-TM#page21.tif
source=9-4-09 Altea-TM#page22.tif
source=9-4-09 Altea-TM#page23.tif
source=9-4-09 Altea-TM#page24.tif
source=9-4-09 Altea-TM#page25.tif
source=9-4-09 Altea-TM#page26.tif
source=9-4-09 Altea-TM#page27.tif
source=9-4-09 Altea-TM#page28.tif
source=9-4-09 Altea-TM#page29.tif
source=9-4-09 Altea-TM#page30.tif
source=9-4-09 Altea-TM#page31.tif
source=9-4-09 Altea-TM#page32.tif
source=9-4-09 Altea-TM#page33.tif
source=9-4-09 Altea-TM#page34.tif
source=9-4-09 Altea-TM#page35.tif
source=9-4-09 Altea-TM#page36.tif

source=9-4-09 Altea-TM#page37.tif
source=9-4-09 Altea-TM#page38.tif
source=9-4-09 Altea-TM#page39.tif
source=9-4-09 Altea-TM#page40.tif
source=9-4-09 Altea-TM#page41.tif
source=9-4-09 Altea-TM#page42.tif
source=9-4-09 Altea-TM#page43.tif
source=9-4-09 Altea-TM#page44.tif
source=9-4-09 Altea-TM#page45.tif
source=9-4-09 Altea-TM#page46.tif
source=9-4-09 Altea-TM#page47.tif
source=9-4-09 Altea-TM#page48.tif
source=9-4-09 Altea-TM#page49.tif
source=9-4-09 Altea-TM#page50.tif
source=9-4-09 Altea-TM#page51.tif
source=9-4-09 Altea-TM#page52.tif
source=9-4-09 Altea-TM#page53.tif
source=9-4-09 Altea-TM#page54.tif

INTELLECTUAL PROPERTY SECURITY AGREEMENT

This **INTELLECTUAL PROPERTY SECURITY AGREEMENT** (this "**Agreement**"), dated as of August 27, 2009, is made by ALTEA THERAPEUTICS CORPORATION, a Delaware corporation ("**Grantor**"), in favor of GE BUSINESS FINANCIAL SERVICES INC., as agent holding liens (in such capacity, together with its successors and assigns, the "**Agent**") for the benefit of itself, the Lenders and GECC (each as defined below).

WITNESSETH:

WHEREAS, pursuant to the Credit and Security Agreement, dated as of June 18, 2007 (as heretofore or hereafter amended, restated, supplemented or otherwise modified from time to time, the "**Venture Loan Credit Agreement**") among Grantor as borrower, any other Borrowers hereafter from time to time party thereto, Agent as administrative agent and GE Business Financial Services Inc. and the other financial institutions from time to time party thereto as lenders (collectively, together with their respective successors and assigns, "**Lenders**"), the Lenders have made certain extensions of credit to the Grantor upon the terms and subject to the conditions set forth therein; and

WHEREAS, pursuant to certain Master Security Agreement dated as of June 22, 2004 (as the same may heretofore have been and may hereafter be amended, modified, supplemented, restated, replaced or refinanced from time to time, specifically including without limitation as amended by the Lien and Collateral Agency Agreement, the "**Master Security Agreement**") between Borrower and General Electric Capital Corporation (together with its successors and assigns, "**GECC**") and certain related "**Notes**" and the other "**Debt Documents**" (as each such term is defined in the Master Security Agreement)), GECC has made certain extensions of credit to the Grantor upon the terms and subject to the conditions set forth therein;

WHEREAS, pursuant to (i) the Venture Loan Credit Agreement and (ii) that certain letter agreement dated March 4, 2008 among Agent, Lenders, Borrower and GECC, as supplemented and amended by that certain letter agreement dated August ____, 2009 among Agent, Lenders, Borrower and GECC (collectively, the "Lien and Collateral Agency Agreement"), Borrower has granted to Agent, for the benefit of Agent, Lenders and GECC, security interests and liens in substantially all of Borrower's assets (other than any "Excluded Collateral" as that term is defined in the Venture Loan Credit Agreement), including without limitation all of Borrower's "**Intellectual Property**" (as that term is defined on Schedule 9.1 to the Venture Loan Credit Agreement (as amended by the Lien and Collateral Agency Agreement)) and specifically including all of Borrower's registered patents, trademarks and copyrights and all of Borrower's filed patent applications, trademark applications and copyright applications,

WHEREAS, pursuant to the Lien and Collateral Agency Agreement, and in consideration of the waivers and agreements provided by Agent, Lenders and GECC thereunder, Grantor has agreed to execute and deliver this Agreement;

NOW, THEREFORE, in consideration of the premises and mutual covenants and agreements provided for herein and in the Lien and Collateral Agency Agreement, and for other good and valuable considerations, the receipt and sufficiency of which are hereby acknowledged by each party hereto, and intending to be legally bound, the parties hereto agree as follows:

Section 1. Defined Terms. Capitalized terms used herein without definition are used as defined in the Venture Loan Credit Agreement.

Section 2. Grant of Security Interest in Intellectual Property Collateral. Grantor, as collateral security for the prompt and complete payment and performance when due (whether at stated maturity, by acceleration or otherwise) of the “**Obligations**” as defined under the Venture Loan Credit Agreement and the “**Equipment Loan Indebtedness**” (as defined in the Lien and Collateral Agency Agreement) hereby mortgages, pledges and hypothecates to the Agent for the benefit of Agent, Lenders and GECC, and grants to the Agent for the benefit of Agent, Lenders and GECC, a Lien on and security interest in, all of Grantor’s right, title and interest in, to and under the following Collateral of Grantor, all whether now owned or hereafter created, arising and/or acquired (the “**Intellectual Property Collateral**”):

(a) all of its trade secrets and rights under any written agreement granting any right to use trade secrets;

(b) all of its copyrights and filed copyright applications and rights under any written agreement granting any right to use copyrights and/or copyright applications, including, without limitation, those referred to on Schedule 1 hereto or on any Schedule to any Supplement (as defined below) delivered hereafter, together with all renewals, reversions and extensions of the foregoing;

(c) all of its trademarks and filed trademark applications and rights under any written agreement granting any right to use trademarks and/or trademark applications, including, without limitation, those referred to on Schedule 2 hereto or on any Schedule to any Supplement delivered hereafter, together with all renewals, reversions and extensions of the foregoing;

(d) all goodwill of the business connected with the use of, and symbolized by, each such trademark and trademark application covered by (b) above;

(e) all of its US Patents and rights under any written agreement granting any right to use US patents including, without limitation, those referred to on Schedule 3 hereto or on any Schedule to any Supplement delivered hereafter, together with all reissues, reexaminations, continuations, continuations-in-part, divisionals, renewals and extensions of the foregoing;

(f) all of its US patent applications and rights under any written agreement granting any right to use US patent applications, including, without limitation, those referred to on Schedule 4 hereto or on any Schedule to any Supplement delivered hereafter, together with all reissues, reexaminations, continuations, continuations-in-part, divisionals, renewals and extensions of the foregoing;

(g) all of its PCT patent applications and rights under any written agreement granting any right to use PCT patent applications, including, without limitation, those referred to on Schedule 5 hereto or on any Schedule to any Supplement delivered hereafter;

(h) all of its foreign patents and patent applications, and rights under any written agreement granting any right to use foreign patents and patent applications, including, without limitation, those referred to on Schedule 6 hereto or on any Schedule to any Supplement delivered hereafter, together with all reissues, reexaminations, continuations, continuations-in-part, divisionals, renewals and extensions of the foregoing;

(i) all other Intellectual Property;

(j) all applications, registrations, claims, products, awards, judgments, amendments, improvements and insurance claims related thereto now or hereafter owned or licensed by Grantor, or any claims for damages by way of any past, present, or future infringement of any of the foregoing, together with all accessions and additions thereto, proceeds and products thereof (including, without limitation, any proceeds resulting under insurance policies); provided, further, that the Intellectual Property Collateral shall include, without limitation, all cash, royalty fees, other proceeds, accounts and general intangibles that consist of rights of payment to or on behalf of Grantor or proceeds from the sale, licensing or other disposition of all or any part of, or rights in, the Intellectual Property Collateral by or on behalf of Grantor;

(j) all income, royalties, proceeds and liabilities at any time due or payable or asserted under and with respect to any of the foregoing, including, without limitation, all rights to sue and recover at law or in equity for any past, present and future infringement, misappropriation, dilution, violation or other impairment thereof, and

(k) all other “**IP Proceeds**” (as that term is defined on Schedule 9.1 to the Venture Loan Credit Agreement (as amended by the Lien and Collateral Agency Agreement)) relating to any of the foregoing.

which such mortgage, pledge, hypothecation, Lien and security interest, and this Agreement, shall continue in full force and effect to secure each of the Obligations and the Equipment Loan Indebtedness until such time as each of the Obligations and the Equipment Loan Indebtedness is indefeasibly paid in full. The Intellectual Property Collateral described in clauses (b), (c), (e), (f), (g) and (h) is referred to herein from time to time as the “**Registered Intellectual Property Collateral**”. Notwithstanding the foregoing, the Intellectual Property Collateral shall not include the Excluded Property.

Section 3. Loan Agreement. The security interest granted pursuant to this Agreement is granted in conjunction with, and in no way limiting, the security interests granted to the Agent pursuant to the Venture Loan Credit Agreement and the other “Security Documents” described therein and the Lien and Collateral Agency Agreement (or the security interests granted separately to GECC pursuant to the Master Security Agreement the other Debt Documents), and Grantor hereby acknowledges and agrees that the rights and remedies of the

Agent with respect to the security interest in the Intellectual Property Collateral made and granted hereby are more fully set forth in the Venture Loan Credit Agreement and the other "Security Documents" described therein and the Lien and Collateral Agency Agreement, the terms and provisions of which are incorporated by reference herein as if fully set forth herein.

Section 4. Registration/Filing. This Agreement is intended by the parties to be filed, and Grantor hereby authorizes Agent to file and record a copy of this Agreement, with the United States Patent and Trademark Office, United States Copyright Office and any applicable foreign intellectual property registry, as applicable.

Section 5. Grantor Remains Liable. Grantor hereby agrees that, anything herein to the contrary notwithstanding, Grantor shall retain full and complete responsibility for the prosecution, defense, enforcement or any other necessary or desirable actions in connection with their Intellectual Property subject to a security interest hereunder.

Section 6. Agreement to Deliver Supplements. Grantor hereby covenants and agrees that promptly upon the acquisition by Grantor of any new Registered Intellectual Property Collateral (including any new copyright application, trademark application, US Patent application, PCT application or foreign patent application and any new copyright, trademark, US Patent or foreign patent issued or registered with respect to any copyright application, trademark application, US Patent application, PCT application or foreign patent application previously listed on Schedules 1 through 6 hereto or the Schedule(s) to any other Supplement delivered to Agent in accordance with this paragraph), and in any event no later than the delivery by Obligor of the Compliance Certificate required to be delivered by Grantor under Section 7(a) below disclosing such new Registered Intellectual Property Collateral, Grantor shall deliver to Agent a duly executed Supplement to this Agreement in the form of Exhibit A hereto, listing all such newly acquired Registered Intellectual Property on Schedule I thereto, or the certification provided for under Section 7(b), as applicable, pursuant to which Grantor shall reconfirm the grant of a security interest in such newly acquired Registered Intellectual Property Collateral to Agent for the benefit of Agent, Lenders and GECC to secure each of the Obligations and the Equipment Loan Indebtedness. Each such Supplement is intended by the parties to be filed, and Grantor hereby authorizes Agent to file and record a copy of each such Supplement, with the United States Patent and Trademark Office, United States Copyright Office and any applicable foreign intellectual property registry, as applicable. Regardless of whether any Supplement is delivered by Grantor, Grantor hereby confirms and agrees that any and all such after-acquired Registered Intellectual Property Collateral, and all Intellectual Property Collateral relating thereto, shall immediately and automatically upon the Grantor's acquisition of any right, title and interest therein become part of the Intellectual Property Collateral hereunder.

Section 7. Agreement to Provide Reporting.

(a) Grantor hereby acknowledges that under the terms of Section 4.1 of the Venture Loan Credit Agreement, Grantor is required to provide a certification regarding any new Registered Intellectual Property Grantor may have acquired with the delivery of each monthly Compliance Certificate, and Grantor hereby reconfirms its agreement to comply with such requirements.

(b) In the event that the Venture Loan Credit Agreement should terminate prior to the termination of this Agreement, Grantor agrees that Grantor shall continue to provide a certification any new Registered Intellectual Property Grantor may have acquired in the form of the IP Compliance Certificate attached as Exhibit B hereto on a quarterly basis no later than ten (10) business days after the end of each calendar quarter until the repayment in full of the Equipment Loan Indebtedness.

Section 8. Representations and Warranties. Grantor hereby represents and warrants to Agent and to the Lenders that Schedules 1 through 6 set forth a full, complete and correct list of (i) all Registered Intellectual Property Collateral registered with or issued by any United States Governmental Authority owned by Grantor as of the date hereof and (ii) all Registered Intellectual Property Collateral registered with or issued by any foreign Governmental Authority which is, to the best of Grantor's knowledge, owned by Grantor as of the date hereof.

Section 9. Events of Default and Remedies. Upon the occurrence of and during the continuance of any Event of Default under the Venture Loan Credit Agreement, the Master Security Agreement, the Notes or any of the other Debt Documents, Agent, in addition to all other rights, options, and remedies granted to Agent under the Venture Loan Credit Agreement (or any other Security Document) or the Lien and Collateral Agency Agreement, or otherwise available to Agent at law or in equity, may exercise, either directly or through one or more assignees or designees, with respect to the Intellectual Property Collateral all rights and remedies granted to it as a secured creditor under the Uniform Commercial Code.

Section 10. Power of Attorney. Without limiting the generality of any power of attorney granted to Agent under the Venture Loan Credit Agreement (or any other Security Document) or the Lien and Collateral Agency Agreement, Grantor hereby authorizes Agent, its successors and assigns, and any officer, employee, attorney or agent thereof, as Grantor's true and lawful attorney-in-fact, with the power (i) to execute and endorse on behalf of and in the name of Grantor any Supplement to this Agreement or other security agreement or similar document or instrument which Agent may deem necessary or desirable in order to create, protect, perfect or enforce the security interest in the Intellectual Property Collateral provided for herein and in each case to file or record with the United States Patent and Trademark Office, the United States Copyright Officer and/or any applicable foreign intellectual property registry in the name of and on behalf of Grantor any such Supplement or other security agreement or similar document or instrument, provided that, unless an Event of Default as defined in Section 7 of this Agreement above shall have occurred and remain outstanding, the powers to execute and endorse (but not to file or record) any Supplement or other security agreement or similar document or instrument described in this clause (i) shall only be exercisable by Agent, its successors and assigns, and any officer, employee, attorney or agent thereof, if Grantor shall have failed to execute any such Supplement, security agreement, document or instrument within ten (10) business days following request therefor from Agent and (ii) after the occurrence and during the continuance of an Event of Default as defined in Section 7 of this Agreement above, to execute and endorse on behalf of and in the name of Grantor any assignment, bill of sale or similar document or instrument which Agent may deem necessary or desirable in order for Agent to assign, pledge, convey or otherwise, sell, transfer title in or dispose of the Intellectual Property Collateral, and in each case to file or record with the United States Patent and Trademark Office,

the United States Copyright Officer and/or any applicable foreign intellectual property registry in the name of and on behalf of Grantor any such assignment or bill of sale or other document executed by Agent, its successors and assigns, and any officer, employee, attorney or agent thereof under this power of attorney. Grantor hereby unconditionally ratifies all that any person authorized under this power of attorney shall lawfully do or cause to be done by virtue hereof and in accordance with the terms of hereof and of the Venture Loan Credit Agreement, the other Security Documents and the Lien and Collateral Agency Agreement. This power of attorney is coupled with an interest and is and shall be irrevocable.

Section 11. Termination. Upon repayment in full of the Obligations and the Equipment Loan Indebtedness and the termination of the Venture Loan Credit Agreement and the Master Security Agreement, or in connection with any transfer by Grantor of any of the Intellectual Property Collateral permitted under the Venture Loan Credit Agreement, the Master Security Agreement, the Notes and the other Debt Documents, Agent, upon the request of Grantor and at Grantor's expense, shall execute, acknowledge, and deliver to Grantor an instrument in writing in recordable form releasing the grant of a security interest in the Intellectual Property Collateral under this Agreement.

Section 12. Counterparts. This Agreement may be executed in any number of counterparts and by different parties in separate counterparts, each of which when so executed shall be deemed to be an original and all of which taken together shall constitute one and the same agreement. Signature pages may be detached from multiple separate counterparts and attached to a single counterpart and signature pages delivered by facsimile or by PDF copy sent via email shall be effective as originals and bind the parties hereto.

Section 13 Conflicts. In all circumstances, so far as possible, the provisions of this Agreement and of the Venture Loan Credit Agreement, the Master Security Agreement, the Notes and the other Debt Documents (in each case, for so long as such Venture Loan Credit Agreement, the Master Security Agreement, the Notes and the other Debt Documents shall remain in effect) and the undertakings, covenants and duties of Grantor hereunder and thereunder shall be interpreted as complementary and supplementary to one another and not as limiting one another, so as to give the fullest and most expansive possible effect to all such provisions, undertakings, covenants and duties and to avoid any conflict or contradict amongst them, provided however that, in the event that, after application of the preceding principals, an irreconcilable conflict exists between any provision of this Agreement and any provision of the Venture Loan Credit Agreement or the Master Security Agreement and any Note issued thereunder, the provisions of the Venture Loan Credit Agreement, the Master Security Agreement or a Note, as applicable, shall govern.

Section 14. Governing Law. THIS AGREEMENT, AND ALL MATTERS RELATING HERETO OR ARISING HEREFROM (WHETHER SOUNDING IN CONTRACT LAW, TORT LAW OR OTHERWISE), SHALL BE GOVERNED BY, AND SHALL BE CONSTRUED AND ENFORCED IN ACCORDANCE WITH, THE LAWS OF THE STATE OF NEW YORK, WITHOUT REGARD TO CONFLICTS OF LAWS PRINCIPLES.

In witness whereof, Grantor has caused this Intellectual Property Security Agreement to be executed and delivered by its duly authorized officer as of the date first set forth above.

GRANTOR:

ALTEA THERAPEUTICS CORPORATION,
as Grantor

By: *Eric Tomlinson*

Name: *Eric TOMLINSON*
Title: *President and CEO*

ACCEPTED AND AGREED
as of the date first above written:

GE BUSINESS FINANCIAL SERVICES INC.
as Agent

By: _____
Name:
Title:

In witness whereof, Grantor has caused this Intellectual Property Security Agreement to be executed and delivered by its duly authorized officer as of the date first set forth above.

GRANTOR:

ALTEA THERAPEUTICS CORPORATION,
as Grantor

By: _____
Name:
Title:

ACCEPTED AND AGREED
as of the date first above written:

GE BUSINESS FINANCIAL SERVICES INC.
as Agent


By: Scott R. Towers
Name: *Scott R. Towers*
Title: *Duly Authorized Signatory*

Acknowledgment of Grantor

STATE OF Georgia)
) ss
COUNTY OF Fulton)

On this 27th day of August 2009 before me personally appeared Eric Tomlinson, proved to me on the basis of satisfactory evidence to be the person who executed the foregoing instrument on behalf of ALTEA THERAPEUTICS CORPORATION, who being by me duly sworn did depose and say that he is an authorized officer of said corporation, that the said instrument was signed on behalf of said corporation as authorized by its Board of Directors and that he acknowledged said instrument to be the free act and deed of said corporation.

Janice A. Baker
Notary Public



ACKNOWLEDGEMENT OF GRANTOR
INTELLECTUAL PROPERTY SECURITY AGREEMENT

TRADEMARK
REEL: 004073 FRAME: 0512

**Schedule 1
to
Intellectual Property Security Agreement**

None.

**Schedule 2
to
Intellectual Property Security Agreement**

[SEE NEXT PAGE]

Trademark	Status	Registration Number	Registration Date	Country
A with Swoops Logo	Registered	3162237	28-Jul-04	European Community
A with Swoops Logo	Registered	4730742	5-Dec-03	Japan
ALTEA THERAPEUTICS	Registered	3162344	8-Sep-04	European Community
ALTEA THERAPEUTICS	Registered	7485113	9-Jun-09	European Community
ALTEA THERAPEUTICS	Registered	4769220	14-May-04	Japan
ALTEA THERAPEUTICS	Registered	5225301	24-Apr-09	Japan
ALTEA THERAPEUTICS	Registered	3,493,784	26-Aug-08	US
ALTEA THERAPEUTICS	Registered	3,582,860	3-Mar-09	US
MEDICINES MADE BETTER.	Registered	3,636,717	9-Jun-09	US
MEDICINES MADE BETTER.	Allowed	77/232,691		US
PASSPORT	Registered	3161288	21-Jul-04	European Community
PASSPORT	Registered	3,544,534	9-Dec-08	US
Swoops Logo	Registered	3161981	12-May-04	European Community
Swoops Logo	Registered	4730743	5-Dec-03	Japan
PASSPORT	Abandoned	(App# 78/231096)		
PASSPORT	Abandoned	(App# 78/216875)		
SKIN-FORT	Abandoned	(App# 78/216870)		
SKINPORE	Abandoned	(App# 78/216864)		
SKINPORT	Abandoned	(App# 78/216796)		
MICROPOR	Abandoned	(App# 76244463)		

LICENSE AGREEMENTS

TITLE:

LICENSE AGREEMENT

NAME OF LICENSEE:

Hospira Inc.

DATE:

July 1, 2008 (amended June 19, 2009)

SUBJECT MATTER:

Altea grants Hospira an exclusive royalty-bearing license to the Licensed Intellectual Property to develop, make, have made, use, sell, offer for sale, import or otherwise commercialize a Licensed Product. Licensed Intellectual Property means Licensed Patent Rights and Licensed Know-How, wherein Licensed Patent Rights means the Patent Rights controlled by Altea as of the Effective Date and During the Term, including but not limited to: (a) Patent Rights set forth on Schedule A; and (b) any Patent Rights constituting Altea Improvements developed during the Term that Cover the Passport Transdermal System. Licensed Product means a pharmaceutical product containing an active ingredient within the Field that is incorporated into or used with the PassPort Transdermal System. The Field includes one or more molecules of the heparin class.

TITLE:

LICENSE AGREEMENT

NAME OF LICENSEE:

Teikoku Seiyaku Co. Ltd.

DATE: January

24, 2006

SUBJECT MATTER:

Altea grants Teikoku an exclusive royalty-bearing license under the Altea Patents and any related know-how in Japan for the development, manufacture and marketing of the Initial Product and Additional Products in Japan.

Altea

Patents means all patents and patent applications owned by or with rights to Altea during the term in Japan. The current list of patents and applications considered Altea Patents is set forth in Exhibit A.

Initial Product means the PassPort System for systemic delivery of apomorphine for treatment of Parkinson's disease.

Additional Product means any one of the 4 products based on the PassPort System and developed by

Teikoku

under the agreement.

License Schedule for IP Security Agreement

6230062-1

TRADEMARK

REEL: 004073 FRAME: 0516

TITLE: DEVELOPMENT AND LICENSE AGREEMENT

NAME OF LICENSEE:
A

Eli Lilly and Company
mylin Pharmaceuticals Inc.

DATE: March

31, 2009

SUBJECT MATTER:

Altea grants to Amylin an exclusive, worldwide royalty-bearing license under the Altea IP Rights and related Know-How to make, have made, use, import, and sell a Licensed Product containing Compound in the Field during the Term. Compound means the compound exenatide.
Altea grants to Lilly and Amylin an exclusive worldwide royalty-bearing license to Additional Compounds. Additional Compounds means incretin mimetics and GLP-1 agonists that are owned or controlled by Lilly or Amylin respectively and that are not Compound or insulin or insulin-based compounds.
Altea grants to Lilly and Amylin a non-exclusive worldwide fully paid up license to Altea Improvements.

TITLE: AMENDED AND RESTATED DEVELOPMENT AND LICENSE AGREEMENT

NAME OF LICENSEE:

Altea Technologies Inc.

DATE: Novem

ber 8, 2002

SUBJECT MATTER:

Altea Development Corporation (later known as Altea Therapeutics Corporation) grants to Altea Technologies Inc. a royalty-free irrevocable exclusive worldwide license to the Licensed Technology to develop, make, have made, market, distribute, use and sell products for Monitoring Applications.
Licensed Technology means the Altea Patents as well as any related Know-How. The Altea Patents mean the Joint Patents (as that terms is defined in the Assignment, Assumption, Delegation and Consent Agreement between ATI, ADC, NIMCO and SpectRx, dated November 2, 2002) and the patents and patent applications set forth on Exhibit 1. Monitoring Applications means extraction of substances from an organism.
Altea Development Corporation (later known as Altea Therapeutics Corporation) grants to Altea Technologies Inc. a royalty-free worldwide irrevocable non-exclusive license to the Blocking Patents for Monitoring Applications. Monitoring Applications means extraction of substances from an organism.

**Schedule 3
to
Intellectual Property Security Agreement**

[SEE NEXT PAGE]

Invention Title	Country	Application Number	Patent Number	Status	Filing Date
Apparatus and Method for Electroporation of Microperated Tissue for Enhancing Flux Rates for Monitoring and Delivery Applications	US	09/036,169	6022316	Granted	06-Mar-1998
Attribute Compensation for Analyte Detection and/or Continuous Monitoring	US	09/786830	6918874	Granted	22-May-2001
Controlled Removal of Biological Membrane by Pyrotechnic Charge For Transmembrane Transport	US	09/353,130	6352506	Granted	14-Jul-1999
Controlled Removal of Biological Membrane by Pyrotechnic Charge For Transmembrane Transport	US	10/040,066	6730028	Granted	29-Oct-2001
Disposal Microporation Porator	US	29/260,181	D574500	Granted	19-May-2006
Dual function assay device	US	09/937865	6704587	Granted	31-Mar-2000
Enhancement of Transdermal Delivery With Ultrasound and Chemical Enhancers	US	08/152,174	5445611	Granted	08-Dec-1993
Enhancement of Transdermal Monitoring Applications with Ultrasound and Chemical Enhancers	US	08/152,442	5458140	Granted	15-Nov-1993
Enhancement of Transdermal Monitoring Applications with Ultrasound and Chemical Enhancers	US	08/465,874	5722397	Granted	06-Jun-1995
Handheld Microporation Applicator	US	29/256,492	D550842	Granted	20-Mar-2006
Integrated alignment devices, system and methods for efficient fluid extraction, substance delivery and other applications	US	10/018001	6925317	Granted	12-Jun-2000
Integrated Poration, Harvesting and Analysis Device, and Method Therefor	US	10/671006	6922578	Granted	25-Sep-2003
Light beam generation, and focusing and redirecting devices	US	10/018913	6951411	Granted	15-Jun-2000
Method and Apparatus For Enhancing Flux Rates of a Fluid in a Microporated Biological Tissue	US	09/036,053	6173202	Granted	06-Mar-1998
Method and Apparatus For Enhancing Flux Rates of a Fluid in a Microporated Biological Tissue	US	09/718,442	6508785	Granted	22-Nov-2000

Invention Title	Country	Application Number	Patent Number	Status	Filing Date
Microporation of Human Skin for Drug Delivery and Monitoring Applications	US	09/208,166	6142939	Granted	09-Dec-1998
Microporation of Human Skin for Monitoring The Concentration of an Analyte	US	08/776,863	5885211	Granted	05-Sep-1997
Microporation Of Tissue For Delivery of Bioactive Agents	US	09/331,124	6527716	Granted	12-Aug-1999
Multiple Mechanical Microporation of Skin or Mucosa	US	09/202,207	6183434	Granted	14-Jun-1999
Photothermal Structure For Biomedical Application and Method Therefor	US	09/622,427	6530915	Granted	20-Oct-2000
Self-removing energy absorbing structure for thermal tissue ablation	US	10/018,015	6685699	Granted	07-Jun-2000
System and Method for Continuous Analyte Monitoring	US	10/435,221	7384396	Granted	08-May-2003
System and method for fluid management in a continuous fluid collection and sensor device	US	09/357452	7037277	Granted	10-Jul-1999
Tissue Interface Device	US	10/130,686	7041057	Granted	11-Sep-2002
Transdermal Drug Delivery Device, Method of Making Same and Method of Using Same	US	09/590,787	6692456	Granted	08-Jun-2000
Transdermal Drug Delivery Device, Method of Making Same and Method of Using Same	US	10/384,795	7141034	Granted	11-Mar-2003
Transdermal Drug Delivery Patch System, Method of Making Same and Method of Using Same	US	10/384,779	7392080	Granted	11-Mar-2003

LICENSE AGREEMENTS

TITLE:

LICENSE AGREEMENT

NAME OF LICENSEE:

Hospira Inc.

DATE:

July 1, 2008 (amended June 19, 2009)

SUBJECT MATTER:

Altea grants Hospira an exclusive royalty-bearing license to the Licensed Intellectual Property to develop, make, have made, use, sell, offer for sale, import or otherwise commercialize a Licensed Product.

Licensed Intellectual Property means Licensed Patent Rights and Licensed Know-How, wherein Licensed Patent Rights means the Patent Rights controlled by Altea as of the Effective Date and During the Term, including but not limited to: (a) Patent Rights set forth on Schedule A; and (b) any Patent Rights constituting Altea Improvements developed during the Term that Cover the Passport Transdermal System. Licensed Product means a pharmaceutical product containing an active ingredient within the Field that is incorporated into or used with the PassPort Transdermal System. The Field includes one or more molecules of the heparin class.

TITLE:

LICENSE AGREEMENT

NAME OF LICENSEE:

Teikoku Seiyaku Co. Ltd.

DATE:

24, 2006

SUBJECT MATTER:

Altea grants Teikoku an exclusive royalty-bearing license under the Altea Patents and any related know-how in Japan for the development, manufacture and marketing of the Initial Product and Additional Products in Japan.

Altea

Patents means all patents and patent applications owned by or with rights to Altea during the term in Japan. The current list of patents and applications considered Altea Patents is set forth in Exhibit A.

Initial Product means the PassPort System for systemic delivery of apomorphine for treatment of Parkinson's disease.

Additional Product means any one of the 4 products based on the PassPort System and developed by Teikoku under the agreement.

Teikoku

License Schedule for IP Security Agreement

6230062-1

TITLE: DEVELOPMENT AND LICENSE AGREEMENT**NAME OF LICENSEE:**
A Eli Lilly and Company
mylin Pharmaceuticals Inc.**DATE:** March 31, 2009**SUBJECT MATTER:** Altea grants to Amylin an exclusive, worldwide royalty-bearing license under the Altea IP Rights and related Know-How to make, have made, use, import, and sell a Licensed Product containing Compound in the Field during the Term. Compound means the compound exenatide.
Altea grants to Lilly and Amylin an exclusive worldwide royalty-bearing license to Additional Compounds. Additional Compounds means incretin mimetics and GLP-1 agonists that are owned or controlled by Lilly or Amylin respectively and that are not Compound or insulin or insulin-based compounds.
Altea grants to Lilly and Amylin a non-exclusive worldwide fully paid up license to Altea Improvements.**TITLE:** AMENDED AND RESTATED DEVELOPMENT AND LICENSE AGREEMENT**NAME OF LICENSEE:** Altea Technologies Inc.**DATE:** Novem ber 8, 2002**SUBJECT MATTER:** Altea Development Corporation (later known as Altea Therapeutics Corporation) grants to Altea Technologies Inc. a royalty-free irrevocable exclusive worldwide license to the Licensed Technology to develop, make, have made, market, distribute, use and sell products for Monitoring Applications.
Licensed Technology means the Altea Patents as well as any related Know-How. The Altea Patents mean the Joint Patents (as that terms is defined in the Assignment, Assumption, Delegation and Consent Agreement between ATI, ADC, NIMCO and SpectRx, dated November 2, 2002) and the patents and patent applications set forth on Exhibit 1. Monitoring Applications means extraction of substances from an organism.
Altea Development Corporation (later known as Altea Therapeutics Corporation) grants to Altea Technologies Inc. a royalty-free worldwide irrevocable non-exclusive license to the Blocking Patents for Monitoring Applications. Monitoring Applications means extraction of substances from an organism.

**Schedule 4
to
Intellectual Property Security Agreement**

[SEE NEXT PAGE]

SCHEDULE 4
INTELLECTUAL PROPERTY SECURITY AGREEMENT

TRADEMARK
REEL: 004073 FRAME: 0523

Invention Title	Country	Application Number	Patent Number	Status	Filing Date
Disposable Microporation Porator Method for Transdermal Delivery of Permanent Substances	US	29/321,862		Pending	24-Jul-2008
Microporation Of Tissue For Delivery of Bioactive Agents	US	10/691,968		Pending	24-Oct-2003
Microporation Of Tissue For Delivery of Bioactive Agents	US	10/284,408		Pending	31-Oct-2002
Microporation Of Tissue For Delivery of Bioactive Agents	US	10/772,472		Pending	06-Feb-2004
Permanent Delivery System and Methods for Use Thereof	US	11/081,448		Published	16-Mar-2005
Transdermal Integrated Actuator Device, Methods of Making and Using Same	US	11/455,899		Published	19-Jun-2006
Transdermal Integrated Actuator Device, Methods of Making and Using Same	US	12/360,698		Pending	27-Jan-2009
Transdermal Integrated Actuator Device, Methods of Making and Using Same	US	10/384,763		Published	11-Mar-2003
Transdermal Porator and Patch System and Method For Using Same	US	12/017,996		Published	22-Jan-2008

LICENSE AGREEMENTS

TITLE: LICENSE AGREEMENT

NAME OF LICENSEE: Hospira Inc.

DATE: July 1, 2008 (amended June 19, 2009)

SUBJECT MATTER: Altea grants Hospira an exclusive royalty-bearing license to the Licensed Intellectual Property to develop, make, have made, use, sell, offer for sale, import or otherwise commercialize a Licensed Product. Licensed Intellectual Property means Licensed Patent Rights and Licensed Know-How, wherein Licensed Patent Rights means the Patent Rights controlled by Altea as of the Effective Date and During the Term, including but not limited to: (a) Patent Rights set forth on Schedule A; and (b) any Patent Rights constituting Altea Improvements developed during the Term that Cover the Passport Transdermal System. Licensed Product means a pharmaceutical product containing an active ingredient within the Field that is incorporated into or used with the PassPort Transdermal System. The Field includes one or more molecules of the heparin class.

TITLE: LICENSE AGREEMENT

NAME OF LICENSEE: Teikoku Seiyaku Co. Ltd.

DATE: January 24, 2006

SUBJECT MATTER: Altea grants Teikoku an exclusive royalty-bearing license under the Altea Patents and any related know-how in Japan for the development, manufacture and marketing of the Initial Product and Additional Products in Japan.
 Altea Patents means all patents and patent applications owned by or with rights to Altea during the term in Japan. The current list of patents and applications considered Altea Patents is set forth in Exhibit A.
 Initial Product means the PassPort System for systemic delivery of apomorphine for treatment of Parkinson's disease.
 Additional Product means any one of the 4 products based on the PassPort System and developed by Teikoku under the agreement.

License Schedule for IP Security Agreement
6230062-1

TITLE: DEVELOPMENT AND LICENSE AGREEMENT**NAME OF LICENSEE:**
AEli Lilly and Company
Amylin Pharmaceuticals Inc.**DATE:** March

31, 2009

SUBJECT MATTER:

Altea grants to Amylin an exclusive, worldwide royalty-bearing license under the Altea IP Rights and related Know-How to make, have made, use, import, and sell a Licensed Product containing Compound in the Field during the Term. Compound means the compound exenatide.

Altea grants to Lilly and Amylin an exclusive worldwide royalty-bearing license to Additional Compounds. Additional Compounds means incretin mimetics and GLP-1 agonists that are owned or controlled by Lilly or Amylin respectively and that are not Compound or insulin or insulin-based compounds.

Altea grants to Lilly and Amylin a non-exclusive worldwide fully paid up license to Altea Improvements.

TITLE:

AMENDED AND RESTATED DEVELOPMENT AND LICENSE AGREEMENT

NAME OF LICENSEE:

Altea Technologies Inc.

DATE: Novem

ber 8, 2002

SUBJECT MATTER:

Altea Development Corporation (later known as Altea Therapeutics Corporation) grants to Altea Technologies Inc. a royalty-free irrevocable exclusive worldwide license to the Licensed Technology to develop, make, have made, market, distribute, use and sell products for Monitoring Applications.

Licensed Technology means the Altea Patents as well as any related Know-How. The Altea Patents mean the Joint Patents (as that terms is defined in the Assignment, Assumption, Delegation and Consent Agreement between ATI, ADC, NIMCO and SpectRx, dated November 2, 2002) and the patents and patent applications set forth on Exhibit 1. Monitoring Applications means extraction of substances from an organism.

Altea Development Corporation (later known as Altea Therapeutics Corporation) grants to Altea Technologies Inc. a royalty-free worldwide irrevocable non-exclusive license to the Blocking Patents for Monitoring Applications. Monitoring Applications means extraction of substances from an organism.

License Schedule for IP Security Agreement

6230062-1

TRADEMARK**REEL: 004073 FRAME: 0526**

**Schedule 5
to
Intellectual Property Security Agreement**

[SEE NEXT PAGE]

Invention Title	Country	Application Number	Patent Number	Status	Filing Date
Alignment Devices and Methods for Fluid Extraction from Tissue and Substance Delivery	PCT	PCT/US2000/016064		National Phase	
Apparatus For Electroporation Through Microporated Tissue	PCT	PCT/US1999/004984		National Phase	05-Mar-1999
Apparatus for Microporation of Biological Membranes Using Thin Film Tissue Interface Devices and Method Therefor	PCT	PCT/US2000/015979		National Phase	08-Jun-2000
Assay Device For Measuring Characteristics of a Fluid on a Continual Basis	PCT	PCT/US2000/009393		National Phase	07-Apr-2000
Attribute Compensation for Analyte Detection and/or Continuous Monitoring	PCT	PCT/US99/20796		Abandoned	
Cast Analyte Diffusion-Limiting Membranes Using Photopolymerizable Hydrophilic Monomers	PCT	PCT/US2001/003304		National Phase	01-Feb-2001
Dual Function Assay Device	PCT	PCT/US2000/008530		National Phase	31-Mar-2000
Integrated Poration, Harvesting and Analysis Device, and Method Therefor	PCT	PCT/US1999/04990		National Phase	
Light beam generation, and focusing and redirecting devices	PCT	PCT/US2000/16576		National Phase	
Method and Apparatus For Enhancing Flux Rate of A Fluid In A Microporated Biological Tissue	PCT	PCT/US1999/004798		National Phase	05-Mar-1999
Method for Transdermal Delivery of Permeant Substances	PCT	PCT/US2004/034715		National Phase	21-Oct-2004
Microporation of Human Skin for Drug Delivery and Monitoring Applications	PCT	PCT/US1996/013865		National Phase	29-Aug-1996
Microporation Of Tissue For Delivery of Bioactive Agents	PCT	PCT/US1997/024127		National Phase	30-Dec-1997
Multiple Mechanical Microporation of Skin or Mucosa	PCT	PCT/US1997/011670		National Phase	03-Jul-1997
Permanent Delivery System and Methods for Use Thereof	PCT	PCT/US2006/023640		National Phase	19-Jun-2006

Invention Title	Country	Application Number	Patent Number	Status	Filing Date
Permeant Delivery System and Methods for Use Thereof	PCT	PCT/US2009/039045		Pending	31-Mar-2009
Photothermal Structure For Biomedical Application and Method Therefor	PCT	PCT/US1999/004929		National Phase	05-Mar-1999
Self-Removing Energy Absorbing Structure for Thermal Tissue Ablation	PCT	PCT/US2000/15665		National Phase	
System and Method for Continuous Analyte Monitoring	PCT	PCT/US1999/16378		National Phase	
System and method for fluid management in a continuous fluid collection and sensor device	PCT	PCT/US1999/16226		National Phase	
System and Method For Monitoring Glucose To Assist In Weight Management and Fitness Training	PCT	PCT/US2000/016507		Abandoned	15-Jun-2000
Tissue Interface Device	PCT	PCT/US2000/31765		National Phase	
Transdermal Drug Delivery Device, Method of Using Same	PCT	PCT/US2003/007310		National Phase	11-Mar-2003
Transdermal Drug Delivery Patch System, Method of Making Same and Method of Using Same	PCT	PCT/US2003/007312		National Phase	11-Mar-2003
Transdermal Integrated Actuator Device, Methods of Making and Using Same	PCT	PCT/US2003/007311		National Phase	11-Mar-2003
Transdermal Porator and Patch System and Method For Using Same	PCT	PCT/US2008/051679		Entering National Phase in AU, CA, EP, JP, and NZ (in process)	22-Jan-2008
Vacuum Device For Substance Extraction	PCT	PCT/US2002/002233		Abandoned	24-Jan-2002

LICENSE AGREEMENTS

TITLE: LICENSE AGREEMENT

NAME OF LICENSEE: Hospira Inc.

DATE: July 1, 2008 (amended June 19, 2009)

SUBJECT MATTER: Altea grants Hospira an exclusive royalty-bearing license to the Licensed Intellectual Property to develop, make, have made, use, sell, offer for sale, import or otherwise commercialize a Licensed Product. Licensed Intellectual Property means Licensed Patent Rights and Licensed Know-How, wherein Licensed Patent Rights means the Patent Rights controlled by Altea as of the Effective Date and During the Term, including but not limited to: (a) Patent Rights set forth on Schedule A; and (b) any Patent Rights constituting Altea Improvements developed during the Term that Cover the Passport Transdermal System. Licensed Product means a pharmaceutical product containing an active ingredient within the Field that is incorporated into or used with the PassPort Transdermal System. The Field includes one or more molecules of the heparin class.

TITLE: LICENSE AGREEMENT

NAME OF LICENSEE: Teikoku Seiyaku Co. Ltd.

DATE: January 24, 2006

SUBJECT MATTER: Altea grants Teikoku an exclusive royalty-bearing license under the Altea Patents and any related know-how in Japan for the development, manufacture and marketing of the Initial Product and Additional Products in Japan. Patents means all patents and patent applications owned by or with rights to Altea during the term in Japan. The current list of patents and applications considered Altea Patents is set forth in Exhibit A. Initial Product means the PassPort System for systemic delivery of apomorphine for treatment of Parkinson's disease. Additional Product means any one of the 4 products based on the PassPort System and developed by Teikoku under the agreement.

License Schedule for IP Security Agreement
6230062-1

TITLE: DEVELOPMENT AND LICENSE AGREEMENT

NAME OF LICENSEE: Eli Lilly and Company
Amylin Pharmaceuticals Inc.

DATE: March 31, 2009

SUBJECT MATTER: Altea grants to Amylin an exclusive, worldwide royalty-bearing license under the Altea IP Rights and related Know-How to make, have made, use, import, and sell a Licensed Product containing Compound in the Field during the Term. Compound means the compound exenatide.
Altea grants to Lilly and Amylin an exclusive worldwide royalty-bearing license to Additional Compounds.
Additional Compounds means incretin mimetics and GLP-1 agonists that are owned or controlled by Lilly or Amylin respectively and that are not Compound or insulin or insulin-based compounds.
Altea grants to Lilly and Amylin a non-exclusive worldwide fully paid up license to Altea Improvements.

TITLE: AMENDED AND RESTATED DEVELOPMENT AND LICENSE AGREEMENT

NAME OF LICENSEE: Altea Technologies Inc.

DATE: November 8, 2002

SUBJECT MATTER: Altea Development Corporation (later known as Altea Therapeutics Corporation) grants to Altea Technologies Inc. a royalty-free irrevocable exclusive worldwide license to the Licensed Technology to develop, make, have made, market, distribute, use and sell products for Monitoring Applications.
Licensed Technology means the Altea Patents as well as any related Know-How. The Altea Patents mean the Joint Patents (as that terms is defined in the Assignment, Assumption, Delegation and Consent Agreement between ATI, ADC, NIMCO and SpectRx, dated November 2, 2002) and the patents and patent applications set forth on Exhibit 1. Monitoring Applications means extraction of substances from an organism.
Altea Development Corporation (later known as Altea Therapeutics Corporation) grants to Altea Technologies Inc. a royalty-free worldwide irrevocable non-exclusive license to the Blocking Patents for Monitoring Applications. Monitoring Applications means extraction of substances from an organism.

**Schedule 6
to
Intellectual Property Security Agreement**

[SEE NEXT PAGE]

8/14/2009

Invention Title	Country	Application Number	Patent Number	Status	Filing Date
Alignment Devices and Methods for Fluid Extraction from Tissue and Substance Delivery	Australia	54820/00		Abandoned	
Alignment Devices and Methods for Fluid Extraction from Tissue and Substance Delivery	Brazil	PI0011506-1		Abandoned	
Alignment Devices and Methods for Fluid Extraction from Tissue and Substance Delivery	Canada	2376952		Abandoned	
Alignment Devices and Methods for Fluid Extraction from Tissue and Substance Delivery	EP	00939791.0	1185202	Granted	
Alignment Devices and Methods for Fluid Extraction from Tissue and Substance Delivery	France	00939791.0	1185202	Granted	
Alignment Devices and Methods for Fluid Extraction from Tissue and Substance Delivery	Germany	60032134.7-08	1185202	Granted	
Alignment Devices and Methods for Fluid Extraction from Tissue and Substance Delivery	Japan	2001-502905		Abandoned	
Alignment Devices and Methods for Fluid Extraction from Tissue and Substance Delivery	Mexico	PA/a/2001/012812		Abandoned	
Alignment Devices and Methods for Fluid Extraction from Tissue and Substance Delivery	United Kingdom	00939791.0	1185202	Granted	
Apparatus For Electroporation Through Microperated Tissue	Australia	29889/99	748376	Granted	05-Mar-1999
Apparatus For Electroporation Through Microperated Tissue	Canada	2,329,169		Pending	05-Mar-1999
Apparatus For Electroporation Through Microperated Tissue	EP	99911185.9		Abandoned	05-Mar-1999
Apparatus For Electroporation Through Microperated Tissue	France	99911185.9	1059960	Granted	05-Mar-1999
Apparatus For Electroporation Through Microperated Tissue	Germany	99911185.9	40064	Granted	05-Mar-1999
Apparatus For Electroporation Through Microperated Tissue	Italy	99911185.9	1059960	Granted	05-Mar-1999
Apparatus For Electroporation Through Microperated Tissue	Japan	2000-534275	3619453	Granted	05-Mar-1999
Apparatus For Electroporation Through Microperated Tissue	Spain	99911185.9	2237091	Granted	05-Mar-1999
Apparatus For Electroporation Through Microperated Tissue	Sweden	99911185.9	2237091	Granted	05-Mar-1999

Invention Title	Country	Application Number	Patent Number	Status	Filing Date
Apparatus For Electroporation Through Microporated Tissue	Switzerland	99911185.9	1059960	Granted	05-Mar-1999
Apparatus For Electroporation Through Microporated Tissue	United Kingdom	99911185.9	1059960	Granted	05-Mar-1999
Apparatus for Microporation of Biological Membranes Using Thin Film Tissue Interface Devices and Method Therefor	Australia	54799/00	780752	Granted	08-Jun-2000
Apparatus for Microporation of Biological Membranes Using Thin Film Tissue Interface Devices and Method Therefor	Austria	00939765.4	E324922	Granted	08-Jun-2000
Apparatus for Microporation of Biological Membranes Using Thin Film Tissue Interface Devices and Method Therefor	Belgium	00939765.4	1189660	Granted	08-Jun-2000
Apparatus for Microporation of Biological Membranes Using Thin Film Tissue Interface Devices and Method Therefor	Canada	2,376,368		Allowed	08-Jun-2000
Apparatus for Microporation of Biological Membranes Using Thin Film Tissue Interface Devices and Method Therefor	China (People's Republic)	00810514.6	ZL00810514.6	Granted	08-Jun-2000
Apparatus for Microporation of Biological Membranes Using Thin Film Tissue Interface Devices and Method Therefor	Cyprus, Republic of	00939765.4	1189660	Granted	08-Jun-2000
Apparatus for Microporation of Biological Membranes Using Thin Film Tissue Interface Devices and Method Therefor	Denmark	00939765.4	1189660	Granted	08-Jun-2000
Apparatus for Microporation of Biological Membranes Using Thin Film Tissue Interface Devices and Method Therefor	EP	05028332.4		Published	22-Dec-2005
Apparatus for Microporation of Biological Membranes Using Thin Film Tissue Interface Devices and Method Therefor	EP	00939765.4	1189660	Regional	08-Jun-2000
Apparatus for Microporation of Biological Membranes Using Thin Film Tissue Interface Devices and Method Therefor	Finland	00939765.4	1189660	Granted	08-Jun-2000

8/14/2009

Invention Title	Country	Application Number	Patent Number	Status	Filing Date
Apparatus for Microporation of Biological Membranes Using Thin Film Tissue Interface Devices and Method Therefor	France	00939765.4	1189660	Granted	08-Jun-2000
Apparatus for Microporation of Biological Membranes Using Thin Film Tissue Interface Devices and Method Therefor	Germany	00939765.4	40033	Granted	08-Jun-2000
Apparatus for Microporation of Biological Membranes Using Thin Film Tissue Interface Devices and Method Therefor	Greece	00939765.4	20060402171	Granted	08-Jun-2000
Apparatus for Microporation of Biological Membranes Using Thin Film Tissue Interface Devices and Method Therefor	Hong Kong	06105787.0		Published	19-May-2006
Apparatus for Microporation of Biological Membranes Using Thin Film Tissue Interface Devices and Method Therefor	Ireland	00939765.4	1189660	Granted	08-Jun-2000
Apparatus for Microporation of Biological Membranes Using Thin Film Tissue Interface Devices and Method Therefor	Italy	00939765.4	1189660	Granted	08-Jun-2000
Apparatus for Microporation of Biological Membranes Using Thin Film Tissue Interface Devices and Method Therefor	Japan	2001-501298		Published	08-Jun-2000
Apparatus for Microporation of Biological Membranes Using Thin Film Tissue Interface Devices and Method Therefor	Japan	2009-41516		Pending	24-Feb-2009
Apparatus for Microporation of Biological Membranes Using Thin Film Tissue Interface Devices and Method Therefor	Luxembourg	00939765.4	1189660	Granted	08-Jun-2000
Apparatus for Microporation of Biological Membranes Using Thin Film Tissue Interface Devices and Method Therefor	Monaco	00939765.4	1189660	Granted	08-Jun-2000
Apparatus for Microporation of Biological Membranes Using Thin Film Tissue Interface Devices and Method Therefor	Netherlands	00939765.4	1189660	Granted	08-Jun-2000

Invention Title	Country	Application Number	Patent Number	Status	Filing Date
Apparatus for Microporation of Biological Membranes Using Thin Film Tissue Interface Devices and Method Therefor	Portugal	00939765.4	1189660	Granted	08-Jun-2000
Apparatus for Microporation of Biological Membranes Using Thin Film Tissue Interface Devices and Method Therefor	South Africa	2001/9966	2001/9966	Abandoned	08-Jun-2000
Apparatus for Microporation of Biological Membranes Using Thin Film Tissue Interface Devices and Method Therefor	Spain	00939765.4	1189660	Granted	08-Jun-2000
Apparatus for Microporation of Biological Membranes Using Thin Film Tissue Interface Devices and Method Therefor	Sweden	00939765.4	1189660	Granted	08-Jun-2000
Apparatus for Microporation of Biological Membranes Using Thin Film Tissue Interface Devices and Method Therefor	Switzerland	00939765.4	1189660	Granted	08-Jun-2000
Apparatus for Microporation of Biological Membranes Using Thin Film Tissue Interface Devices and Method Therefor	United Kingdom	00939765.4	1189660	Granted	08-Jun-2000
Assay Device For Measuring Characteristics of a Fluid on a Continual Basis	Australia	42169/00		Abandoned	07-Apr-2000
Assay Device For Measuring Characteristics of a Fluid on a Continual Basis	Brazil	P10009581-8		Abandoned	07-Apr-2000
Assay Device For Measuring Characteristics of a Fluid on a Continual Basis	Canada	2,366,753		Abandoned	07-Apr-2000
Assay Device For Measuring Characteristics of a Fluid on a Continual Basis	Chile	2646-2001		Pending	02-Nov-2001
Assay Device For Measuring Characteristics of a Fluid on a Continual Basis	EP	00921911.4		Abandoned	07-Apr-2000
Assay Device For Measuring Characteristics of a Fluid on a Continual Basis	Japan	2000-608941		Abandoned	07-Apr-2000
Assay Device For Measuring Characteristics of a Fluid on a Continual Basis	Mexico	PA/a/2001/010156		Abandoned	07-Apr-2000

Invention Title	Country	Application Number	Patent Number	Status	Filing Date
Attribute Compensation for Analyte Detection and/or Continuous Monitoring	Brazil	PI0102366-7		Pending	10-Sep-1999
Attribute Compensation for Analyte Detection and/or Continuous Monitoring	Australia	35107/01		Abandoned	
Attribute Compensation for Analyte Detection and/or Continuous Monitoring	Canada	2343762		Abandoned	
Attribute Compensation for Analyte Detection and/or Continuous Monitoring	EP	99945635.3		Abandoned	
Attribute Compensation for Analyte Detection and/or Continuous Monitoring	Japan	2000-569690		Pending	
Attribute Compensation for Analyte Detection and/or Continuous Monitoring	Mexico	PA/a/2001/002601		Abandoned	
Cast Analyte Diffusion-Limiting Membranes Using Photopolymerizable Hydrophilic Monomers	Australia	2001036612		Abandoned	01-Feb-2001
Cast Analyte Diffusion-Limiting Membranes Using Photopolymerizable Hydrophilic Monomers	Canada	2,398,810		Abandoned	01-Feb-2001
Cast Analyte Diffusion-Limiting Membranes Using Photopolymerizable Hydrophilic Monomers	EP	01908778.2		Abandoned	01-Feb-2001
Cast Analyte Diffusion-Limiting Membranes Using Photopolymerizable Hydrophilic Monomers	Japan	2001-555864		Abandoned	01-Feb-2001
Controlled Removal of Biological Membrane by Pyrotechnic Charge For Transmembrane Transport	Australia	2003213541	2003213541	Granted	17-Jul-2003
Controlled Removal of Biological Membrane by Pyrotechnic Charge For Transmembrane Transport	Australia	49964/99	759738	Granted	14-Jul-1999
Controlled Removal of Biological Membrane by Pyrotechnic Charge For Transmembrane Transport	Austria	99934045.8	1124607	Granted	14-Jul-1999
Controlled Removal of Biological Membrane by Pyrotechnic Charge For Transmembrane Transport	Belgium	99934045.8	1124607	Granted	14-Jul-1999

8/14/2009

Invention Title	Country	Application Number	Patent Number	Status	Filing Date
Controlled Removal of Biological Membrane by Pyrotechnic Charge For Transmembrane Transport	Canada	2,355,044	2,355,044	Granted	14-Jul-1999
Controlled Removal of Biological Membrane by Pyrotechnic Charge For Transmembrane Transport	Cyprus, Republic of	99934045.8	1124607	Granted	14-Jul-1999
Controlled Removal of Biological Membrane by Pyrotechnic Charge For Transmembrane Transport	Denmark	99934045.8	1124607	Granted	14-Jul-1999
Controlled Removal of Biological Membrane by Pyrotechnic Charge For Transmembrane Transport	EP	08014701.0		Published	19-Aug-2008
Controlled Removal of Biological Membrane by Pyrotechnic Charge For Transmembrane Transport	EP	99934045.8	1124607	Regional	14-Jul-1999
Controlled Removal of Biological Membrane by Pyrotechnic Charge For Transmembrane Transport	Finland	99934045.8	1124607	Granted	14-Jul-1999
Controlled Removal of Biological Membrane by Pyrotechnic Charge For Transmembrane Transport	France	99934045.8	1124607	Granted	14-Jul-1999
Controlled Removal of Biological Membrane by Pyrotechnic Charge For Transmembrane Transport	Germany	99934045.8	40033	Granted	14-Jul-1999
Controlled Removal of Biological Membrane by Pyrotechnic Charge For Transmembrane Transport	Greece	99934045.8	1124607	Granted	14-Jul-1999
Controlled Removal of Biological Membrane by Pyrotechnic Charge For Transmembrane Transport	Ireland	99934045.8	1124607	Granted	14-Jul-1999
Controlled Removal of Biological Membrane by Pyrotechnic Charge For Transmembrane Transport	Italy	99934045.8	1124607	Granted	14-Jul-1999
Controlled Removal of Biological Membrane by Pyrotechnic Charge For Transmembrane Transport	Luxembourg	99934045.8	1124607	Granted	14-Jul-1999
Controlled Removal of Biological Membrane by Pyrotechnic Charge For Transmembrane Transport	Monaco	99934045.8	1124607	Granted	14-Jul-1999
Controlled Removal of Biological Membrane by Pyrotechnic Charge For Transmembrane Transport	Netherlands	99934045.8	1124607	Granted	14-Jul-1999
Controlled Removal of Biological Membrane by Pyrotechnic Charge For Transmembrane Transport	Portugal	99934045.8	1124607	Granted	14-Jul-1999

8/14/2009

Invention Title	Country	Application Number	Patent Number	Status	Filing Date
Controlled Removal of Biological Membrane by Pyrotechnic Charge For Transmembrane Transport	Spain	99934045.8	1124607	Granted	14-Jul-1999
Controlled Removal of Biological Membrane by Pyrotechnic Charge For Transmembrane Transport	Sweden	99934045.8	1124607	Granted	14-Jul-1999
Controlled Removal of Biological Membrane by Pyrotechnic Charge For Transmembrane Transport	Switzerland	99934045.8	1124607	Granted	14-Jul-1999
Dual function assay device	Australia	40540/00		Abandoned	
Dual function assay device	Brazil	P10009468-4		Abandoned	
Dual function assay device	Canada	2366746		Abandoned	
Dual function assay device	Chile			Abandoned	
Dual function assay device	EP	919932.4		Abandoned	
Dual Function Assay Device	Japan	2000-608939		Abandoned	31-Mar-2000
Dual function assay device	Japan	2000-608939		Abandoned	
Dual function assay device	Mexico	PA/a/2001/009830		Abandoned	
Fluid Management in a Continuous Fluid Collection and Sensor Device	Australia	51106/99	770388	Abandoned	20-Jul-1999
Fluid Management in a Continuous Fluid Collection and Sensor Device	Australia	2004201488		Abandoned	07-Apr-2004
Integrated Alignment Devices, Systems, and Method For Efficient Fluid Extraction, Substance Delivery and Other Applications	Australia	54820/00		Abandoned	12-Jun-2000
Integrated Poration, Harvesting and Analysis Device, and Method Therefor	EP	99911191.7 1059883		Granted	
Integrated Poration, Harvesting and Analysis Device, and Method Therefor	United Kingdom	99911191.7 1059883		Granted	
Integrated Tissue Poration Fluid Harvesting and Analysis Device and Method Therefor	EP	99911184.2	1059882	Granted	
Integrated Tissue Poration Fluid Harvesting and Analysis Device and Method Therefor	France	99911184.2	1059882	Granted	
Integrated Tissue Poration Fluid Harvesting and Analysis Device and Method Therefor	Germany	699 37 338.7-08	1059882	Granted	
Integrated Tissue Poration Fluid Harvesting and Analysis Device and Method Therefor	United Kingdom	99911184.2	1059882	Granted	

Invention Title	Country	Application Number	Patent Number	Status	Filing Date
Light Beam Generation and Focusing Device	Australia	57426/00		Abandoned	
Light Beam Generation and Focusing Device	Canada	2377331		Abandoned	
Light beam generation, and focusing and redirecting devices	EP	942857.4		Abandoned	
Method and Apparatus For Enhancing Flux Rate of A Fluid In A Microporated Biological Tissue	Belgium	99911120.6	1059939	Granted	05-Mar-1999
Enhancing Flux Rate of A Fluid In A Microporated Biological Tissue	Denmark	99911120.6	1059939	Granted	05-Mar-1999
Method and Apparatus For Enhancing Flux Rate of A Fluid In A Microporated Biological Tissue	EP	99911120.6	1059939	Regional	05-Mar-1999
Method and Apparatus For Enhancing Flux Rate of A Fluid In A Microporated Biological Tissue	France	99911120.6	1059939	Granted	05-Mar-1999
Method and Apparatus For Enhancing Flux Rate of A Fluid In A Microporated Biological Tissue	Germany	99911120.6	39911	Granted	05-Mar-1999
Method and Apparatus For Enhancing Flux Rate of A Fluid In A Microporated Biological Tissue	Ireland	99911120.6	1059939	Granted	05-Mar-1999
Method and Apparatus For Enhancing Flux Rate of A Fluid In A Microporated Biological Tissue	Italy	99911120.6	1059939	Granted	05-Mar-1999
Method and Apparatus For Enhancing Flux Rate of A Fluid In A Microporated Biological Tissue	Japan DIV	2008-157298		Pending	16-Jun-2008
Method and Apparatus For Enhancing Flux Rate of A Fluid In A Microporated Biological Tissue	Netherlands	99911120.6	1059939	Granted	05-Mar-1999
Method and Apparatus For Enhancing Flux Rate of A Fluid In A Microporated Biological Tissue	Spain	99911120.6	1059939	Granted	05-Mar-1999
Method and Apparatus For Enhancing Flux Rate of A Fluid In A Microporated Biological Tissue	Sweden	99911120.6	1059939	Granted	05-Mar-1999
Method and Apparatus For Enhancing Flux Rate of A Fluid In A Microporated Biological Tissue	Switzerland	99911120.6	1059939	Granted	05-Mar-1999
Method and Apparatus For Enhancing Flux Rate of A Fluid In A Microporated Biological Tissue	United Kingdom	99911120.6	1059939	Granted	05-Mar-1999

8/14/2009

Invention Title	Country	Application Number	Patent Number	Status	Filing Date
Method and Apparatus For Enhancing Flux Rates of a Fluid in a Microporated Biological Tissue	Australia	29840/99	747794	Granted	05-Mar-1999
Method and Apparatus For Enhancing Flux Rates of a Fluid in a Microporated Biological Tissue	Canada	2,637,760		Pending	28-Aug-2008
Method and Apparatus For Enhancing Flux Rates of a Fluid in a Microporated Biological Tissue	Canada	2,329,167	2329167	Granted	05-Mar-1999
Method and Apparatus For Enhancing Flux Rates of a Fluid in a Microporated Biological Tissue	Japan	2000-534238		Published	05-Mar-1999
Method and Apparatus For Enhancing Flux Rates of a Fluid in a Microporated Biological Tissue	Japan	2007-64243		Published	13-Mar-2007
Method and Apparatus For Enhancing Flux Rates of a Fluid in a Microporated Biological Tissue	Japan DIV	2007-64243		Pending	
Method for Transdermal Delivery of Permeant Substances	Australia	2004284914		Pending	21-Oct-2004
Method for Transdermal Delivery of Permeant Substances	Belarus	20060489		Pending	21-Oct-2004
Method for Transdermal Delivery of Permeant Substances	Canada	2,543,534		Pending	21-Oct-2004
Method for Transdermal Delivery of Permeant Substances	China (People's Republic)	200480037936.6		Pending	21-Oct-2004
Method for Transdermal Delivery of Permeant Substances	EP	04795823.6		Published	21-Oct-2004
Method for Transdermal Delivery of Permeant Substances	India	2959/DELNP/2006		Pending	21-Oct-2004
Method for Transdermal Delivery of Permeant Substances	Israel	175088		Pending	21-Oct-2004
Method for Transdermal Delivery of Permeant Substances	Japan	2006-536749		Published	21-Oct-2004
Method for Transdermal Delivery of Permeant Substances	Korea, Republic of	10-2006-7007936		Pending	21-Oct-2004
Method for Transdermal Delivery of Permeant Substances	Norway	20062342		Pending	21-Oct-2004
Method for Transdermal Delivery of Permeant Substances	Russian Federation	2006117783		Allowed 21-Oct-2004	
Method for Transdermal Delivery of Permeant Substances	Russian Federation	2009122870		Pending	15-Jun-2009
Method for Transdermal Delivery of Permeant Substances	Singapore	200602677-7	121588	Granted	21-Oct-2004

8/14/2009

Invention Title	Country	Application Number	Patent Number	Status	Filing Date
Method for Transdermal Delivery of Permeant Substances	Ukraine	200605662		Pending	21-Oct-2004
Microporation of Human Skin for Drug Delivery and Monitoring Applications	Australia	68631/96	707065	Granted	29-Aug-1996
Microporation of Human Skin for Drug Delivery and Monitoring Applications	Brazil	PI9610012-5		Pending	27-Feb-1998
Microporation of Human Skin for Drug Delivery and Monitoring Applications	Canada	2,199,002	2199002	Granted	29-Aug-1996
Microporation of Human Skin for Drug Delivery and Monitoring Applications	China (People's Republic)	96196671.8	ZL96196671.8	Granted	29-Aug-1996
Microporation of Human Skin for Drug Delivery and Monitoring Applications	EP	96929098.0		Abandoned	29-Aug-1996
Microporation of Human Skin for Drug Delivery and Monitoring Applications	EP	05011002.2		Published	20-May-2005
Microporation of Human Skin for Drug Delivery and Monitoring Applications	Hong Kong	98110113.4	1009321	Granted	24-Aug-1998
Microporation of Human Skin for Drug Delivery and Monitoring Applications	Israel	123,379	123379	Granted	29-Aug-1996
Microporation of Human Skin for Drug Delivery and Monitoring Applications	Japan	9-510552	3899427	Granted	29-Aug-1996
Microporation of Human Skin for Drug Delivery and Monitoring Applications	Japan	2006-38655		Abandoned	14-Feb-2006
Microporation of Human Skin for Drug Delivery and Monitoring Applications	Norway	98.0878		Pending	29-Aug-1996
Microporation of Human Skin for Drug Delivery and Monitoring Applications	Russian Federation	98105681	2209031	Granted	29-Aug-1996
Microporation of Human Skin for Drug Delivery and Monitoring Applications	Singapore	9802059-7	51619	Granted	29-Aug-1996
Microporation of Human Skin for Drug Delivery and Monitoring Applications	Turkey	1998/347		Abandoned	29-Aug-1996

8/14/2009

Invention Title	Country	Application Number	Patent Number	Status	Filing Date
Microporation Of Human Skin for Drug Delivery and Monitoring Applications	United Kingdom	9702766.8	2307414	Granted	29-Aug-1996
Microporation Of Tissue For Delivery of Bioactive Agents	Austria	03002035.8	1314400	Granted	28-Jan-2003
Microporation Of Tissue For Delivery of Bioactive Agents	Belgium	03002035.8	1314400	Granted	28-Jan-2003
Microporation Of Tissue For Delivery of Bioactive Agents	Canada	2,276,312		Pending	30-Dec-1997
Microporation Of Tissue For Delivery of Bioactive Agents	Denmark	03002035.8	1314400	Granted	28-Jan-2003
Microporation Of Tissue For Delivery of Bioactive Agents	EP	03002035.8	1314400	Regional	28-Jan-2003
Microporation Of Tissue For Delivery of Bioactive Agents	EP	97952676.1		Abandoned	30-Dec-1997
Microporation Of Tissue For Delivery of Bioactive Agents	Finland	03002035.8	1314400	Granted	28-Jan-2003
Microporation Of Tissue For Delivery of Bioactive Agents	France	03002035.8	1314400	Granted	28-Jan-2003
Microporation Of Tissue For Delivery of Bioactive Agents	Germany	03002035.8	39941	Granted	28-Jan-2003
Microporation Of Tissue For Delivery of Bioactive Agents	Ireland	03002035.8	1314400	Granted	28-Jan-2003
Microporation Of Tissue For Delivery of Bioactive Agents	Italy	03002035.8	1314400	Granted	28-Jan-2003
Microporation Of Tissue For Delivery of Bioactive Agents	Japan	10-530298		Abandoned	30-Dec-1997
Microporation Of Tissue For Delivery of Bioactive Agents	Japan	2008-157298		Pending	16-Jun-2008
Microporation Of Tissue For Delivery of Bioactive Agents	Netherlands	03002035.8	1314400	Granted	28-Jan-2003
Microporation Of Tissue For Delivery of Bioactive Agents	Spain	03002035.8	1314400	Granted	28-Jan-2003
Microporation Of Tissue For Delivery of Bioactive Agents	Sweden	03002035.8	1314400	Granted	28-Jan-2003
Microporation Of Tissue For Delivery of Bioactive Agents	Switzerland	03002035.8	1314400	Granted	28-Jan-2003
Microporation Of Tissue For Delivery of Bioactive Agents	United Kingdom	03002035.8	1314400	Granted	28-Jan-2003
Multiple Mechanical Microporation of Skin or Mucosa	Belgium	97936041.9	921840	Granted	03-Jul-1997
Multiple Mechanical Microporation of Skin or Mucosa	Canada	2,259,437	2259437	Granted	03-Jul-1997
Multiple Mechanical Microporation of Skin or Mucosa	Denmark	97936041.9	921840	Granted	03-Jul-1997

8/14/2009

Invention Title	Country	Application Number	Patent Number	Status	Filing Date
Multiple Mechanical Microporation of Skin or Mucosa	EP	97936041.9	921840	Regional	03-Jul-1997
Multiple Mechanical Microporation of Skin or Mucosa	Germany	97936041.9	40002	Granted	03-Jul-1997
Multiple Mechanical Microporation of Skin or Mucosa	Ireland	97936041.9	921840	Granted	03-Jul-1997
Multiple Mechanical Microporation of Skin or Mucosa	Italy	97936041.9	921840	Granted	03-Jul-1997
Multiple Mechanical Microporation of Skin or Mucosa	Japan	10-504488	3942640	Granted	03-Jul-1997
Multiple Mechanical Microporation of Skin or Mucosa	Netherlands	97936041.9	921840	Granted	03-Jul-1997
Multiple Mechanical Microporation of Skin or Mucosa	Spain	97936041.9	921840	Granted	03-Jul-1997
Multiple Mechanical Microporation of Skin or Mucosa	Sweden	97936041.9	921840	Granted	03-Jul-1997
Multiple Mechanical Microporation of Skin or Mucosa	Switzerland	97936041.9	921840	Granted	03-Jul-1997
Multiple Mechanical Microporation of Skin or Mucosa	United Kingdom	97936041.9	921840	Granted	03-Jul-1997
Permanent Delivery System and Methods for Use Thereof	Australia	2006261325		Pending	19-Jun-2006
Permanent Delivery System and Methods for Use Thereof	Canada	2,612,511		Pending	19-Jun-2006
Permanent Delivery System and Methods for Use Thereof	China (People's Republic)	200680029851.2		Published	19-Jun-2006
Permanent Delivery System and Methods for Use Thereof	EP	06773439.2		Published	19-Jun-2006
Permanent Delivery System and Methods for Use Thereof	India	10268/DELNP/2007		Pending	19-Jun-2006
Permanent Delivery System and Methods for Use Thereof	Israel	188145		Pending	19-Jun-2006
Permanent Delivery System and Methods for Use Thereof	Japan	2008-517185		Published	19-Jun-2006
Permanent Delivery System and Methods for Use Thereof	Malaysia	PI20062862		Pending	16-Jun-2006
Permanent Delivery System and Methods for Use Thereof	Mexico	MX/a/2007/016310		Pending	17-Dec-2007
Permanent Delivery System and Methods for Use Thereof	Singapore	200718661-2		Pending	19-Jun-2006
Permanent Delivery System and Methods for Use Thereof	Taiwan	095121835		Published	16-Jun-2006
Permanent Delivery System and Methods for Use Thereof	Thailand	601002797		Pending	16-Jun-2006

8/14/2009

Invention Title	Country	Application Number	Patent Number	Status	Filing Date
Photothermal Structure For Biomedical Application and Method Therefor	Canada	2,323,160		Abandoned	05-Mar-1999
Photothermal Structure For Biomedical Application and Method Therefor	EP	99909882.5		Abandoned	05-Mar-1999
Photothermal Structure For Biomedical Application and Method Therefor	Japan	2000-534239		Published	05-Mar-1999
Photothermal Structure For Biomedical Applications, And Method Therefor	Canada	2323160		Abandoned	
Photothermal Structure For Biomedical Applications, And Method Therefor	EP	99909882.5		Abandoned	
Photothermal Structure For Biomedical Applications, And Method Therefor	Japan	2000-534239		Abandoned	
Self-Removing Energy Absorbing Structure for Thermal Tissue Ablation	EP	939642.5		Abandoned	
System and Method for Continuous Analyte Monitoring	Australia	2003271036		Abandoned	
System and Method for Continuous Analyte Monitoring	Australia	50042/99		Abandoned	
System and Method for Continuous Analyte Monitoring	Brazil	PI9912333-9		Abandoned	
System and Method for Continuous Analyte Monitoring	Canada	2338203		Abandoned	
System and Method For Continuous Analyte Monitoring	EP	99934149.8	1098594	Regional	20-Jul-1999
System and Method for Continuous Analyte Monitoring	EP	1098594		Granted	
System and Method for Continuous Analyte Monitoring	Japan	2000-560827		Pending	
System and Method for Continuous Analyte Monitoring	Mexico	PA/a/2001/000698		Abandoned	
System and Method For Continuous Analyte Monitoring	Switzerland	99934149.8	1098594	Granted	20-Jul-1999
System and method for fluid management in a continuous fluid collection and sensor device	Brazil	PI9912339-8		Abandoned	
System and method for fluid management in a continuous fluid collection and sensor device	Canada	2338292		Abandoned	

8/14/2009

Invention Title	Country	Application Number	Patent Number	Status	Filing Date
System and method for fluid management in a continuous fluid collection and sensor device	EP	99935678.5	1098589	Granted	
System and method for fluid management in a continuous fluid collection and sensor device	Japan	2000-560818		Abandoned	
System and method for fluid management in a continuous fluid collection and sensor device	Mexico	PA/a/2001/000759		Abandoned	
System and method for fluid management in a continuous fluid collection and sensor device	United Kingdom	99935678.5	1098589	Granted	
Tissue Interface Device	Australia	17786/01		Abandoned	
Tissue Interface Device	Brazil	PI0015716-3		Abandoned	17-Nov-2000
Tissue Interface Device	Canada	2390893		Abandoned	
Tissue Interface Device	Chile	1049-2002		Abandoned	
Tissue Interface Device	EP	980533.4		Pending	
Tissue Interface Device	Japan	2001-537619		Abandoned	
Tissue Interface Device	Mexico	PA/a/2002/005068		Abandoned	
Transdermal Drug Delivery Device, Method of Using Same	Canada	2,478,822		Pending	11-Mar-2003
Transdermal Drug Delivery Patch System, Method of Making Same and Method of Using Same	EP	03744634.1		Published	11-Mar-2003
Transdermal Drug Delivery Patch System, Method of Making Same and Method of Using Same	Japan	2003-576024		Published	11-Mar-2003

LICENSE AGREEMENTS

TITLE: LICENSE AGREEMENT

NAME OF LICENSEE: Hospira Inc.

DATE: July 1, 2008 (amended June 19, 2009)

SUBJECT MATTER: Altea grants Hospira an exclusive royalty-bearing license to the Licensed Intellectual Property to develop, make, have made, use, sell, offer for sale, import or otherwise commercialize a Licensed Product. Licensed Intellectual Property means Licensed Patent Rights and Licensed Know-How, wherein Licensed Patent Rights means the Patent Rights controlled by Altea as of the Effective Date and During the Term, including but not limited to: (a) Patent Rights set forth on Schedule A; and (b) any Patent Rights constituting Altea Improvements developed during the Term that Cover the Passport Transdermal System. Licensed Product means a pharmaceutical product containing an active ingredient within the Field that is incorporated into or used with the PassPort Transdermal System. The Field includes one or more molecules of the heparin class.

TITLE: LICENSE AGREEMENT

NAME OF LICENSEE: Teikoku Seiyaku Co. Ltd.

DATE: January 24, 2006

SUBJECT MATTER: Altea grants Teikoku an exclusive royalty-bearing license under the Altea Patents and any related know-how in Japan for the development, manufacture and marketing of the Initial Product and Additional Products in Japan.
 Patents means all patents and patent applications owned by or with rights to Altea during the term in Japan. The current list of patents and applications considered Altea Patents is set forth in Exhibit A.
 Initial Product means the PassPort System for systemic delivery of apomorphine for treatment of Parkinson's disease.
 Additional Product means any one of the 4 products based on the PassPort System and developed by Teikoku under the agreement.

License Schedule for IP Security Agreement
 6230062-1

TITLE: DEVELOPMENT AND LICENSE AGREEMENT

NAME OF LICENSEE:
A Eli Lilly and Company
mylin Pharmaceuticals Inc.

DATE: March 31, 2009

SUBJECT MATTER: Altea grants to Amylin an exclusive, worldwide royalty-bearing license under the Altea IP Rights and related Know-How to make, have made, use, import, and sell a Licensed Product containing Compound in the Field during the Term. Compound means the compound exenatide.
Altea grants to Lilly and Amylin an exclusive worldwide royalty-bearing license to Additional Compounds.
Additional Compounds means incretin mimetics and GLP-1 agonists that are owned or controlled by Lilly or Amylin respectively and that are not Compound or insulin or insulin-based compounds.
Altea grants to Lilly and Amylin a non-exclusive worldwide fully paid up license to Altea Improvements.

TITLE: AMENDED AND RESTATED DEVELOPMENT AND LICENSE AGREEMENT

NAME OF LICENSEE: Altea Technologies Inc.

DATE: November 8, 2002

SUBJECT MATTER: Altea Development Corporation (later known as Altea Therapeutics Corporation) grants to Altea Technologies Inc. a royalty-free irrevocable exclusive worldwide license to the Licensed Technology to develop, make, have made, market, distribute, use and sell products for Monitoring Applications.
Licensed Technology means the Altea Patents as well as any related Know-How. The Altea Patents mean the Joint Patents (as that terms is defined in the Assignment, Assumption, Delegation and Consent Agreement between ATI, ADC, NIMCO and SpectRx, dated November 2, 2002) and the patents and patent applications set forth on Exhibit 1. Monitoring Applications means extraction of substances from an organism.
Altea Development Corporation (later known as Altea Therapeutics Corporation) grants to Altea Technologies Inc. a royalty-free worldwide irrevocable non-exclusive license to the Blocking Patents for Monitoring Applications. Monitoring Applications means extraction of substances from an organism.

License Schedule for IP Security Agreement

6230062-1

EXHIBIT A

SUPPLEMENT TO INTELLECTUAL PROPERTY SECURITY AGREEMENT

THIS SUPPLEMENT TO INTELLECTUAL PROPERTY SECURITY AGREEMENT (the "Supplement") made as of this ___ day of _____, by ALTEA THERAPEUTICS CORPORATION, a Delaware corporation ("**Grantor**"), in favor of GE BUSINESS FINANCIAL SERVICES INC., as agent holding liens (in such capacity, together with its successors and assigns, the "**Agent**") for the benefit of itself, the Lenders and GECC (each as defined in the IP Agreement referenced below):

WITNESSETH

WHEREAS, Grantor and Agent are parties to a certain Intellectual Property Security Agreement dated as of July __, 2009 (as the same heretofore may have been and hereafter may be amended, restated, supplemented or otherwise modified from time to time, the "IP Agreement"). Capitalized terms used herein but not otherwise defined shall have the meanings given thereto in the IP Agreement; and

WHEREAS, pursuant to the terms of the IP Agreement, Grantor, as collateral security for the prompt and complete payment and performance when due (whether at stated maturity, by acceleration or otherwise) of the Obligations and the Equipment Loan Indebtedness has mortgaged, pledged and hypothecated to the Agent for the benefit of Agent, Lenders and GECC, and granted to the Agent for the benefit of Agent, Lenders and GECC, a Lien on and security interest in, all of Grantor's right, title and interest in, to and under the Intellectual Property Collateral of Grantor, all whether now owned or hereafter created, arising and/or acquired.

WHEREAS, also pursuant to the IP Agreement, Grantor has agreed that upon the acquisition by Grantor of any new Registered Intellectual Property Collateral, Grantor shall deliver to Agent a Supplement to the IP Agreement in the form of Exhibit A to such IP Agreement pursuant to which Grantor shall reconfirm the grant by it of a security interest in all such newly acquired Registered Intellectual Property Collateral, which such Supplement is intended by the parties to be filed with the United States Patent and Trademark Office, United States Copyright Office and any applicable foreign intellectual property registry, as applicable;

NOW, THEREFORE, in consideration of the premises set forth herein and for other good and valuable consideration, receipt and sufficiency of which are hereby acknowledged by each party hereto, and intending to be legally bound, and with the foregoing background and recitals incorporated by reference, Grantor agrees as follows:

1. Grant and Reaffirmation of Grant of Security Interests. Grantor, as collateral security for the prompt and complete payment and performance when due (whether at stated maturity, by acceleration or otherwise) of the Obligations and the Equipment Loan Indebtedness hereby mortgages, pledges and hypothecates to the Agent for the benefit of Agent, Lenders and

GECC, and grants to the Agent for the benefit of Agent, Lenders and GECC, a Lien on and security interest in (and hereby reaffirms its prior mortgage, pledge, hypothecation and grant to Agent under the Venture Loan Credit Agreement, the other Security Documents, the Lien and Collateral Agency Agreement and the IP Agreement with respect to) all of Grantor's right, title and interest in, to and under:

(a) the newly acquired Registered Intellectual Property Collateral listed on Schedule 1 to this Supplement (together with all reissues, reexaminations, continuations, continuations-in-part, divisionals, renewals and extensions of the foregoing),

(b) all goodwill of the business connected with the use of, and symbolized by, any trademark and trademark application covered by (a) above;

(c) all applications, registrations, claims, products, awards, judgments, amendments, improvements and insurance claims related thereto now or hereafter owned or licensed by Grantor, or any claims for damages by way of any past, present, or future infringement of any of the foregoing, together with all accessions and additions thereto, proceeds and products thereof (including, without limitation, any proceeds resulting under insurance policies); including, without limitation, all cash, royalty fees, other proceeds, accounts and general intangibles that consist of rights of payment to or on behalf of Grantor or proceeds from the sale, licensing or other disposition of all or any part of, or rights in, such Intellectual Property Collateral by or on behalf of Grantor;

(d) all income, royalties, proceeds and liabilities at any time due or payable or asserted under and with respect to any of the foregoing, including, without limitation, all rights to sue and recover at law or in equity for any past, present and future infringement, misappropriation, dilution, violation or other impairment thereof, and

(e) all other IP Proceeds relating to any of the foregoing.

Grantor agrees that all such newly acquired Intellectual Property Collateral described shall be included in and be part of the Intellectual Property Collateral under and otherwise subject to all of the terms and provisions of the IP Agreement. Grantor hereby authorizes Agent to file and record a copy of this Supplement with the United States Patent and Trademark Office, United States Copyright Office and any applicable foreign intellectual property registry, as applicable

2. Representations and Warranties. Grantor hereby represents and warrants to Agent and to the Lenders that Schedule I hereto sets forth a full, complete and correct list of (i) all Registered Intellectual Property Collateral registered with or issued by any United States Governmental Authority owned by Grantor as of the date hereof not listed on Schedules 1 through 6 to the original IP Agreement or any Schedule to any other Supplement to the original IP Agreement delivered by Grantor since the date thereof and (ii) all Registered Intellectual Property Collateral registered with or issued by any foreign Governmental Authority which is, to the best of Grantor's knowledge, owned by Grantor as of the date hereof not listed on Schedules 1 through 6 to the original IP Agreement or any Schedule to any other Supplement to the original IP Agreement delivered by Grantor since the date thereof (the "New Registered Intellectual Property Collateral").

3. Incorporation of the IP Agreement. The terms and provisions of the IP Agreement are hereby incorporated by reference and this Supplement shall be considered an amendment and supplement to and part of the IP Agreement, all of the provisions of which IP Agreement are and remain in full force and effect.

4. Governing Law. THIS SUPPLEMENT AND ALL MATTERS RELATING HERETO OR ARISING HEREFROM (WHETHER SOUNDING IN CONTRACT LAW, TORT LAW OR OTHERWISE), SHALL BE GOVERNED BY, AND SHALL BE CONSTRUED AND ENFORCED IN ACCORDANCE WITH, THE LAWS OF THE STATE OF NEW YORK, WITHOUT REGARD TO CONFLICTS OF LAWS PRINCIPLES.

[Signatures on Following Page]
[Remainder of Page Left Intentionally Blank]

IN WITNESS WHEREOF, Grantor has duly executed this Supplement to the IP Security Agreement as of the date first written above.

GRANTOR:

ALTEA THERAPEUTICS CORPORATION,
as Grantor

By: _____
Name:
Title:

ACCEPTED AND AGREED
as of the date first above written:

GE BUSINESS FINANCIAL SERVICES INC.
as Agent

By: _____
Name:
Title:

[Signature Page to IP Security Agreement – Supplement Date _____]

SCHEDULE I TO SUPPLEMENT TO TRADEMARK SECURITY AGREEMENT
DATED _____

121647.01078/21810140v.3
15261077.1.BUSINESS

TRADEMARK
REEL: 004073 FRAME: 0554

EXHIBIT B

FORM OF COMPLIANCE CERTIFICATE

Date: _____, _____

This certificate is given by _____, the _____ of Altea Therapeutics Corporation ("Altea"), pursuant to a certain Intellectual Property Security Agreement dated as of August __, 2009 between Altea and GE Business Financial Services Inc. as agent ("Agent") (as the same heretofore may have been and hereafter may be amended, restated, supplemented or otherwise modified from time to time, the "IP Agreement"). Capitalized terms used herein without definition shall have the meanings set forth in the IP Agreement.

The undersigned, in his/her capacity as an officer of Altea, hereby certifies to Agent that, except as noted on **Schedule 1** attached hereto:

(i) Altea has not acquired, by purchase, by the approval or granting of any application for registration (whether or not such application was previously disclosed to Agent), by filing of any new application or otherwise or otherwise, any Registered Intellectual Property Collateral, or acquired rights under a license as a licensee with respect to any such Registered Intellectual Property Collateral (or any such application for the registration of Intellectual Property) owned by another Person, that has not previously been reported to Agent on Schedules 1 through 6 to the original IP Agreement or any Schedule to any other Supplement to the original IP Agreement delivered by Grantor since the date thereof. Except as noted on **Schedule 1** attached hereto, or as noted on Schedules 1 through 6 to the original IP Agreement or any Schedule to any other Supplement to the original IP Agreement delivered by Altea since the date thereof, Altea entered into any license as licensor encumbering any of its right, title or interest in or to any of its Registered Intellectual Property Collateral, and

(ii) Altea has not breached or violated any of the provisions of the IP Agreement.

The foregoing certifications are made as of this ____ day of _____, 20__.

Sincerely,

By _____
Name _____
Title _____

Schedules to Compliance Certificate

Schedule 1 –Newly Acquired Intellectual Property and Intellectual Property Licenses